

FIG.1

Malignant Breast  
96102003G H9C65



FIG.2A

Malignant Breast  
9609C033R H9C65




FIG.2B

Normal Breast.  
9712C030G H9C65



FIG.2C

MB8 Cell Line  
H9C65




FIG.2D

Malignant Breast  
96102003G H95C30




FIG.3A

Malignant Breast  
9609C033R H95C30




FIG.3B

Normal Breast  
9712C030G H95C30



FIG.3C

MB8 Cell Line  
H95C30




FIG.3D





FIG.4A



anti-BU101 PAb 10923


FIG.4B

1 2 3 4 3



anti-Mam PAb 10931

FIG.4C



anti-myc MAb

FIG.5A




FIG.5B




FIG. 6A






FIG. 6B



10918 10923 11543 10931  
Polyclonal Antisera, 1:5000

FIG.6C



H85 H68 H111 myc  
Monoclonal Antibodies 1:50

FIG.6D



1 2



FIG.7




FIG. 8A




FIG. 8B




FIG.9




FIG.10

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15




FIG. 11A

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15






FIG. 11B




anti-BU101.3, 10923, 1:5000  
sample reduced and boiled

FIG.12A



anti-MAM.1, 10931, 1:5000  
sample reduced and boiled

FIG.12B



Polyclonal Antibody 10923  
anti-BU101.3

FIG.13A


Reduced                      Not Reduced  
42 43 44 45 46 47 48    42 43 44 45 46 47 48



Polyclonal Antibody 10931  
anti-MAM.1


FIG.13B






anti-BU101 polyclonal 10923

FIG.14A



anti-Mam polyclonal

FIG.14B



anti-myc, 1:5000

FIG.15

Met Lys Leu Ser Val Cys Leu Leu Leu Val Thr Leu Ala Leu Cys Cys  
1 5 10 15  
Tyr Gln Ala Asn Ala Glu Phe Cys Pro Ala Leu Val Ser Glu Leu Leu  
20 25 30  
Asp Phe Phe Phe Ile Ser Glu Pro Leu Phe Lys Leu Ser Leu Ala Lys  
35 40 45  
Phe Asp Ala Pro Pro Glu Ala Val Ala Ala Lys Leu Gly Val Lys Arg  
50 55 60  
Cys Thr Asp Gln Met Ser Leu Gln Lys Arg Ser Leu Ile Ala Glu Val  
65 70 75 80  
Leu Val Lys Ile Leu Lys Lys Cys Ser Val  
85 90

FIG.16

## ASSEMBLY OF BS106 FROM INDIVIDUAL EXPRESSED TAGS




FIG.17

## &gt;BS106 CONSENSUS




CGGCTCGAGCTCTTAGGCTTTGAAGCATTTTTGTCTGTGCTCCCT  
GATCTTCAGGTCACCACCATGAAGTTCTTAGCAGTCCTGGTACTC  
TTGGGAGTTTCCATCTTTCTGGTCTCTGCCAGAATCCGACAACA  
GCTGCTCCAGCTGACACGTATCCAGCTACTGGTCCTGCTGATGAT  
GAAGCCCCTGATGCTGAAACCACTGCTGCTGCAACCACTGCGACC  
ACTGCTGCTCCTACCACTGCAACCACCGCTGCTTCTACCACTGCT  
CGTAAAGACATTCCAGTTTTACCCAAATGGGTTGGGGATCTTCCG  
AATGGTAGAGTGTGTCCCTGAGATGGAATCAGCTTGAGTCTTCTG  
CAATTGGTCACAACTATTCATGCTTCCTGTGATTTTCATCCAATA  
CTTACCTTGCCTACGATATCCCCTTTATCTCTAATCAGTTTATTT  
TCTTTCAAATAAAAAATAACTATGAGCAACATAAAAAAAAAAAAAA


FIG.18A

## &gt;BS106 TRANSLATION

MKFLAVLVLLGVSI FLVSAQNPTTAAPADTYPATGPADDEAPDAE  
TTAAATTATTAAPT TATTAASTTARKDIPVLPKWVGDL PNGRVCP


FIG.18B






Anti-BU101.3 Polyclonal

FIG.20A




Anti-Mam.1 Polyclonal

FIG.20B



Anti-BU101.3 Polyclonal

FIG.20C



Anti-Mam.1 Polyclonal

FIG.20D



Correlations Between Marker Expression and Clinical and Molecular Parameters

	BU101	BS106	Mamaglobin	CK19	
T Stage	0.003 (NS)	-0.13 (NS)	-0.03 (NS)	-0.03 (NS)	N=95
Grade	-0.14 (NS)	0.12 (NS)	0.03 (NS)	0.06 (NS)	N=90
N Stage	0.05 (NS)	0.06 (NS)	0.04 (NS)	0.19 (NS)	N=85
Nodes +	-0.02 (NS)	0.01 (NS)	0.05 (NS)	0.23 (NS)	N=85
ER	-0.18 (NS)	-0.10 (NS)	<b>-0.23 (p=0.02)</b>	-0.18 (NS)	N=99
PR	-0.18 (NS)	-0.10 (NS)	<b>-0.23 (p=0.02)</b>	-0.18 (NS)	N=99
HER2	-0.12 (NS)	<b>0.36 (p=0.003)</b>	0.11 (NS)	0.02 (NS)	N=67
P53	-0.19 (NS)	-0.16 (NS)	-0.02 (NS)	-0.14 (NS)	N=77
BU101	-----	-0.05 (NS)	0.37 (p=0.0001)	-0.04 (NS)	N=101
BS106	-0.05 (NS)	-----	0.004 (NS)	0.07 (NS)	N=101
Mamm	0.37 (p=0.0001)	0.004 (NS)	-----	0.07 (NS)	N=101

Pearson product moment correlations were calculated between each pair of variables. The only significant relationships observed are bolded and have included p values. NS=not significant

FIG.21